EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies

Chen Liang, Zhaoqian He, Qiang Tao, Xiang Tang, Lingmin Jiang iD, Xinyue Tu, Zonghao Liu, Hua Chen, Feihu Xie, Yun Zheng iD

Journal of Clinical Medicine · 13.12.2023 · 12 (24) · 7665

DOI: 10.3390/jcm12247665 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.12.2023. Verfasst von Chen Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China, accounting for the majority of primary liver cancer cases. Liver resection is the preferred curative method for early-stage HCC. However, up to 80–85% of patients have already missed the opportunity of radical surgery due to tumor advances at the time of consultation. Conversion therapies are a series of medications and treatments for initially inoperable patients. For early-stage unresectable HCC (uHCC) patients, conversion therapies are designed to meet surgical requirements by increasing the volume of the residual liver. Meanwhile, for advanced cases, conversion therapies strive for tumor shrinkage and down-staging, creating the opportunity for liver resection or liver transplantation. This review summarizes the latest advances in conversion therapies and highlights their potential for improving the survival benefit of patients with uHCC.

Schlagwörter

Stichwörter der Autor:innen

conversion therapyhepatocellular carcinomaunresectable liver cancer

Autor:innen und Institutionen

  • Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

ORCID-Profile: Lingmin Jiang, Yun Zheng

Zitieren

APA

Liang, C., He, Z., Tao, Q., Tang, X., Jiang, L., Tu, X., Liu, Z., Chen, H., Xie, F., & Zheng, Y. (2023). From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies. Journal of Clinical Medicine, 12(24), 7665. https://doi.org/10.3390/jcm12247665

Vancouver

Liang C, He Z, Tao Q, Tang X, Jiang L, Tu X, et al. From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies. Journal of Clinical Medicine. 2023;12(24):7665. doi:10.3390/jcm12247665

BibTeX
@article{Liang2023,
  author = {Liang, Chen and He, Zhaoqian and Tao, Qiang and Tang, Xiang and Jiang, Lingmin and Tu, Xinyue and Liu, Zonghao and Chen, Hua and Xie, Feihu and Zheng, Yun},
  title = {From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {24},
  pages = {7665},
  doi = {10.3390/jcm12247665}
}
Kostenlos starten →